Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 615 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR FDA Extends Approval of Pembrolizumab for Classical Hodgkin Lymphoma October 20, 2020 Safety Analysis Shows that Durvalumab Treatment After SBRT Is Feasible in... March 27, 2021 Expanding Research on Dormant Cancer Cells Aims to Prevent Metastasis April 10, 2025 Thinking outside the chromosome – how ecDNA is challenging conventional thinking November 11, 2022 Load more HOT NEWS A tribute to Professor Anne Charlton No Clinical Benefit from Nivolumab Plus Ipilimumab Over Nivolumab Alone as... Exosomes May Help Tumors Evade Immune System High Tumour Mutation Burden Fails to Predict Response to Immune Checkpoint...
